Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04917757 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas

Study acronym: NAPACA
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 31, 2024 to Dec 31, 2025v4
  2. Results first posted: Oct 8, 2024v3 Show 4 more changesShow less
    • Primary completion date: May 31, 2021 to Aug 31, 2019
    • Enrollment target: 4374 to 3656
    • Study completion date: Dec 31, 2021 to Dec 31, 2024
    • Secondary endpoint revised
  3. Secondary endpoint revised
    • Eligibility criteria expanded, about 3 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary aim of the study is to assess mortality and cardiovascular events potentially linked to cortisol excess in patients with adrenal incidentalomas stratified by cortisol values following the 1-mg overnight dexamethasone test.
Trial Details
NCT Number NCT04917757
Lead Sponsor Wuerzburg University Hospital
Collaborators: European Network for the Study of Adrenal Tumors
Conditions
(from sponsor)		 Adrenal Incidentaloma
Related terms Adrenal incidentaloma
Enrollment 3,656 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov